Plus Therapeutics, Inc. Sustainability Profile
Plus Therapeutics, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing innovative therapies for cancer treatment. Founded in 2016, the company has made significant strides in the field of radiopharmaceuticals, particularly with its lead product, Rhenium-186 NanoLiposome, designed for targeted cancer therapy. With a commitment to advancing treatment options, Plus Therapeutics operates primarily in the oncology sector, leveraging its proprietary technology to enhance the delivery of therapeutic agents. The company has garnered attention for its unique approach to radiotherapy, positioning itself as a leader in the development of next-generation cancer treatments. Notable achievements include successful clinical trials that underscore its potential to improve patient outcomes in challenging cancer types.
DitchCarbon Score
How does Plus Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Plus Therapeutics, Inc.'s score of 17 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Plus Therapeutics, Inc.'s reported carbon emissions
Plus Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Plus Therapeutics may not have established formal commitments to reduce carbon emissions or may be in the early stages of developing such initiatives. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate commitments. However, without specific emissions data or reduction targets, it is challenging to assess Plus Therapeutics' position relative to industry standards. As the company progresses, it may consider adopting frameworks such as the Science Based Targets initiative (SBTi) to align its climate strategies with global climate goals.
How Carbon Intensive is Plus Therapeutics, Inc.'s Industry?
How Carbon Intensive is Plus Therapeutics, Inc.'s Location?
Plus Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Plus Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
